

FACULTY/PRESENTER DISCLOSURE

Faculty

DR. MARC S. SABATINE

Relationships with commercial interests:

- **Advisory Board:** Alnylam; Amgen; AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Esperion; Intarcia; Ionis; Janssen Research and Development; Medicines Company; MedImmune; Merck; MyoKardia; Novartis
- **Grant or honorarium:** Abbott Laboratories; Amgen; AstraZeneca; Brigham and Women's Hospital; CCRN; Critical Diagnostics; Daiichi-Sankyo; Eisai; Genzyme; Gilead; GlaxoSmithKline; Intarcia; Janssen Research and Development; Medicines Company; MedImmune; Merck; Novartis; Poxel; Pfizer; Roche Diagnostics; Takeda
- **Clinical trial:** Abbott Laboratories; Amgen; AstraZeneca; Critical Diagnostics; Daiichi-Sankyo; Eisai; Genzyme; Gilead; GlaxoSmithKline; Intarcia; Janssen Research and Development; Medicines Company; MedImmune; Merck; Novartis; Poxel; Pfizer; Roche Diagnostics; Takeda

DISCLOSURE OF COMMERCIAL SUPPORT

This program has received financial support from Amgen in the form of an educational grant.

This program has received in-kind support from Amgen in the form of logistical support.

Potential for conflict(s) of interest:

- Marc Sabatine has received payment/funding from companies whose product(s) are being discussed in this program
 - Amgen
 - Sanofi

MITIGATING POTENTIAL BIAS

- All content has been reviewed by a physician steering committee and the College of Family Physicians Canada
- All data has been sourced from evidence that is clinically accepted
- All support used in justification of patient care recommendations conform to generally accepted standards